bluuebunny/crossref_metadata_2025 huggingface dataset:
FRI490 Association Between TSH Levels And Early Development Of Secondary Sexual Characteristics Among Children With Congenital Hypothyroidism
Authors: Nunez Stosic Mariana Mercedes , Seeherunvong Tossaporn
Published: October 2023

Disclosure: M.M. Nunez Stosic: None. T. Seeherunvong: None.

Although hypothyroidism typically delays puberty, early pubertal development in patients with hypothyroidism and markedly elevated TSH levels has been reported. Recent studies investigated the association between thyroid function and timing of puberty among normal children. Jung et al. reported an association between serum TSH and LH levels in girls with central precocious puberty. By contrast Wilken et al. found an association between serum T4 level and onset of pubarche but not thelarche among female subjects. We investigated the association between serum TSH levels and onset of secondary sexual characteristics among patients with congenital hypothyroidism. A retrospective study was conducted including girls and boys aged ≥6 years and ≤ 18 years with confirmed primary congenital hypothyroidism who were seen in our pediatric endocrinology clinic at University of Miami, between May 2012 and May 2022. Age of onset of secondary sexual characteristics (SSC) such as body odor, acne, axillary hair, pubic hair, breast/testicular development was recorded. Early onset of SSC was defined by its presence in girls younger than 8 years and in boys younger than 9 years. Onset of SSC was considered early normal if it occurred between 8-9.5 years in girls and between 9-10.5 years in boys. A third group of patients were those with onset of SSC after 9.5 years in girls and after 10.5 years in boys. We recorded the serum TSH levels from age 6-8 years in girls and from 7-9 years in boys. We determined the average TSH levels and the proportion of the serum TSH level above normal range. IBM SPSS Statistics software version 28.0.0.0(190) was used for data analysis. Fifty-seven subjects with a history of congenital hypothyroidism, 36 girls (63.2%) and 21 boys (36.8%) were included in the study. Seventeen patients (29.8%) had early or early normal onset of SSC. The prevalence was more frequent among girls than boys, 14% and 3% respectively (p value= 0.046). Among all 57 subjects, only 9 had normal serum TSH. The mean proportion of TSH levels above normal limit was 62.4% in patients with early or normal early onset of SSC. By contrast, the mean proportion of serum TSH level above normal limit was 53.7% in those patients who had neither early nor early normal onset of SSC (p value=0.044). In summary, early and early normal onset of SSC was associated with higher TSH levels in children with congenital hypothyroidism. Further studies with a larger number of subjects will be needed to define further the specific SSC most associated with an abnormally elevated TSH.

Presentation: Friday, June 16, 2023
FRI536 Association Between Thyroid Cancer And Thyroid Autoimmunity: A Systematic Review
Authors: Pessoa Bruna , Loch Batista Rafael
Published: October 2023

Disclosure: B. Pessoa: None. R.L. Batista: None.

Thyroid cancer (TC) is the most frequent endocrine neoplasm with growing incidence worldwide. Autoimmune thyroid disorders, especially Hashimoto's thyroiditis (HT), are also highly prevalent worldwide. The association between thyroid cancer and thyroid autoimmunity has long been suggested. However, several studies that have assessed the relationship between thyroid cancer and thyroid autoimmunity had inconsistent findings. While some studies did not show a significant relationship between these topics, others confirmed this association. Objective: The present study aims to summarize and update the data on literature about the association between thyroid cancer and thyroid autoimmunity. Materials and methods: A systematic literature search was conducted in the Medline database (PubMed) in November 2022, including all published scientific papers from 2016 to 2022. The association was analyzed in two ways: the prevalence of thyroid cancer in patients with thyroid autoimmunity versus those without and the progression of thyroid cancer according to autoimmunity status. Results: A total of 137 papers were first identified. After the screening for eligibility, only 10 matched all inclusion criteria and were included in this study. Collectively, these studies included 7,873 patients. Half of the studies showed a higher prevalence of TC in patients with thyroid autoimmunity and an associated risk for TC development. An estimate OR for TC in these studies ranged from 1.45 to 3.14. There is also evidence showing that TC in cases of thyroid autoimmunity are smaller (≤ 10 mm in diameter) than those without thyroid autoimmunity, which may suggest thyroid cancers are diagnosed at an early stage. Regarding the progression of thyroid cancer according to autoimmunity status, the results are inconsistent. While some studies reported findings to support thyroid autoimmunity as a protective factor against TC based on less tumor size, capsule invasion, extra-thyroidal extension, lymph node metastasis, and distant metastasis, others showed that 50% of patients with detectable TgAb had more lymph node metastasis than those with undetectable TgAb. On the other hand, no significant association between TPOAb and lymph node metastasis was shown. Conclusion: the association between thyroid cancer and thyroid autoimmunity appears to be a relevant mechanism to elucidate. However, no definitive data justify a clear connection between thyroid autoimmunity and thyroid cancer. Furthermore, there is insufficient data to determine if thyroid autoimmunity leads to different progression and prognoses of thyroid cancer.

Presentation: Friday, June 16, 2023
FRI555 A Misdiagnosis Of TSH-secreting Adenoma With Thyrotoxicosis In A Patient With Graves’ Disease
Authors: Huynh James , Makawi Alladdin , Elshimy Ghada
Published: October 2023

Disclosure: J. Huynh: None. A. Makawi: None. G. Elshimy: None.

Introduction: Modern healthcare relies on laboratory and imaging results for accurate diagnosis and medical decision-making. However, the collection and distillation of laboratory results is a multi-step process with the potential for error at each stage. This may result in diagnostic errors. A review of salient cases is one avenue to improving awareness of the risk for failure in the laboratory assessment process. We present one such case of a patient initially referred to neurosurgery for management of a thyroid stimulating hormone (TSH) secreting microadenoma, which is a rare disease and accounts for less than 1% of all pituitary adenomas, with incongruent laboratory presentation including elevation in TSH and free T4. Endocrinology consultation prompted further investigations which led to the diagnosis of Graves’ disease with a concomitant nonfunctional pituitary microadenoma. Case Presentation: This is a case of a 61-year-old white male who presented with 30-lb weight loss, insomnia, palpitations, and diaphoresis. Initial thyroid stimulating hormone (TSH) from outside facility was > 90 mcIU/mL with elevated free T4 of 23.4 pg/mL. MRI of the brain shows a 3x3 mm pituitary microadenoma raising concern for an atypical case of TSH-secreting adenoma. The patient referred to Neurosurgery for evaluation by primary care. Endocrinology was consulted for evaluation prior to any surgical intervention. A large goiter was noted on exam. Clinical presentation was highly concern for Graves’ disease. Repeated labs included undetectable TSH with FT4 of 4.4 pg/mL and free T3 12.9 pg/ml. TPO-ab was elevated at 17.1 IU/mL. TSIg index was low. Ultrasound of the thyroid gland revealed a normal thyroid without nodules. He was diagnosed with Graves’ disease and was initiated on methimazole and propranolol with symptomatic improvement. His pituitary panels continued to show suppressed TSH pre and post treatment with no other significant pituitary abnormalities hence the diagnosis of a concomitant nonfunctional pituitary microadenoma was made. Discussion: Ultimately, the initial TSH-secreting microadenoma has deemed a misdiagnosis and he was subsequently treated appropriately for Graves’ disease with normalization of thyroid functions. Standard of care for any laboratory abnormalities is to assess for reproducibility of the result. In our patient, subsequent in-house and outside assays were unable to demonstrate elevation of both TSH and FT4. Instead, the patient had suppressed TSH with elevated FT4, without evidence of nodules consistent with Graves’ disease. Treatment of Graves’ disease differs greatly from the treatment of TSH-secreting pituitary adenoma, which includes surgical resection, radiotherapy, and/or, a somatostatin analog based on the clinical picture. Correct diagnosis prevented our patients from unnecessary surgical complications and lifelong morbidity.

Presentation: Friday, June 16, 2023
FRI571 Maternal Graves’ Disease With Foetal Thyrotoxicosis And Goitre
Authors: Fennell David , Walsh Jennifer , Hatunic Mensud
Published: October 2023

Disclosure: D. Fennell: None. J. Walsh: None. M. Hatunic: None.

Background: Graves’ disease (GD) is an uncommon condition affecting 0.2% of pregnancies. Foetal and neonatal thyrotoxicosis occurs in between 1-5% of pregnant patients with a history of GD, typically beyond 20 weeks gestation. Given its potential for serious morbidity and mortality, prompt recognition and treatment of the condition is essential. Clinical case: A 34-year-old female was referred at 21+2 weeks’ gestation from another hospital due to concerning cardiac findings noted on routine prenatal ultrasound (US). Her medical history was significant for GD (TRAb positive) with moderate ophthalmopathy and total thyroidectomy ten months prior, on L-thyroxine 150 mcg daily. Foetal tachycardia 170-180bpm was noted, with US showing with right ventricular hypertrophy, small pericardial effusion and a 1.9 x 2.7 x 2.8cm neck mass, suspicious for foetal goitre. Maternal laboratory studies showed TSH 2.38mIU/L (0.27-4.2), FT4 16.0pmol/L (12-22), TPO antibody negative <3.0IU/ml and TRAb markedly elevated >30IU/L (0-1.8). A diagnosis of foetal thyrotoxicosis secondary to placental passage of maternal TRAb was made. She was commenced on carbimazole 20mg twice daily at 21+6 weeks’ gestation as treatment, with the goal of normalising foetal heart rate. Careful, weekly follow-up with US scanning noted gradual improvement in the foetus’ condition, with resolution of pericardial effusion and foetal heart rate normalisation. Maternal TFTs were monitored weekly and she remained euthyroid on increased dose L-thyroxine (200 mcg daily). Multidisciplinary team consensus was to proceed with elective Caesarean section at 34 weeks’ gestation, to avoid risk of airway obstruction from foetal goitre. A healthy male infant was born with spontaneous breathing and normal heart rate at delivery. Apgar scores were 9 and 9 at 1 and 5 minutes. Maternal carbimazole was immediately discontinued post-delivery and L-thyroxine reduced to 150 mcg daily. She had an uncomplicated recovery post-Caesarean section. The infant was closely monitored in the neonatal ICU. On day five of life, he became unwell, developing a supraventricular tachycardia. Thyrotoxicosis was confirmed on laboratory studies (FT4 >100pmol/L). Carbimazole, propranolol and Lugol’s iodine were all used as treatment. Thyroid hormone levels normalised within days, with gradual clinical improvement. He was discharged home well four weeks after birth, remaining on propranolol 0.3mg four times daily and carbimazole 0.5mg twice daily, with close paediatric outpatient follow-up planned. Conclusion: Foetal thyrotoxicosis is a rare condition, but can cause serious morbidity, as demonstrated here. First trimester maternal thyroid antibody testing is recommended for all patients with a history of GD, to identify those at risk. Management of the condition is complex, requiring multidisciplinary specialist input for favourable outcome.

Presentation: Friday, June 16, 2023
SAT468 Assessment of Peak Systolic Velocity of Various Thyroid Arteries
Authors: Raju Karishma , Ibrahim Katherine , Morkos Michael
Published: October 2023

Disclosure: K. Raju: None. K. Ibrahim: None. M. Morkos: None.

Objective: Peak systolic velocity (PSV) assessment is a useful bedside tool in the evaluation of patients presenting with thyrotoxicosis. Graves’ disease is characterized by increased PSV values, and it was previously reported that inferior arteries had higher PSV as compared to the superior arteries. We aimed to assess the peak systolic velocity (PSV) in the superior and inferior thyroid arteries bilaterally in patients with Graves’ disease and determine the arteries with the highest values. Research and Design Methods: This is a retrospective cross-sectional study of patients diagnosed with Graves’ disease at an academic outpatient endocrinology clinic from August 2019 to November 2022. The peak systolic velocities were measured using spectral Doppler ultrasound at the superior and inferior thyroid arteries bilaterally. Descriptive statistics, Chi square, and t-test were utilized to describe and compare data. Results: We identified 58 patients who presented for initial assessment of Graves’ disease, 48 (82.8%) were newly diagnosed and presented for initial assessment, 45 (77.6%) were female, 36 (62.1%) Caucasian, and 18 (31.0%) African American. Mean age (± standard deviation) 44.6 ± 13.9 years, TSH 0.27 ± 0.85 (reference range [ref] 0.4 - 4.2), free T4 2.2 ± 1.6 (ref 0.6 - 1.5), and total T3 242.9 ± 169.9 (ref 80 - 179). The mean PSV at the right inferior artery (RIA; n=43) 40.2 ± 18.3 cm/sec, right superior artery (RSA; n=37) 40.0 ± 24.5 cm/sec, left inferior artery (LIA; n=45) 38.2 ± 15.1 cm/sec, and left superior artery (LSA: n=33) 35.1 ± 17.2 cm/sec (P=0.16). The highest PSV was in the LIA in 32.8% of patients, followed by RSA (22.4%), RIA (20.7%), and LSA (15.5%). There was no statistically significant difference between right versus left or superior versus inferior arteries (P=0.17). Seven patients (12.1%) had elevated PSV in superior thyroid arteries while having normal values in the inferior thyroid arteries. Conclusion: PSV assessment of the four thyroid arteries in patients with Graves’ disease did not reveal a consistent pattern. Assessment of the superior and inferior thyroid arteries bilaterally is recommended to avoid missing the artery with the highest PSV.

Presentation Date: Saturday, June 17, 2023
SAT480 Diagnosing Dysphagia Due to Thyroid Nodules by Thyroid Ultrasound and the Effectiveness of Radiofrequency Ablation
Authors: Idrees Zarwa , Morkos Michael
Published: October 2023

Disclosure: Z. Idrees: None. M. Morkos: None.

Objective: Thyroid nodules can cause dysphagia by direct esophageal compression. Diagnosis of esophageal compression during thyroid ultrasound has not been described. Radiofrequency ablation of thyroid nodules may be able to treat the compressive symptoms. Methods: We present a case series of four patients who presented with dysphagia due to compressive nodular goiter. Thyroid ultrasound was performed by a certified endocrinologist (Endocrine Certification in Neck Ultrasound) who assessed esophageal compression. Nodules were treated with thyroid radiofrequency ablation (RFA). Symptom score, ranging from zero (no symptoms) to ten (severe symptoms), was used to assess the severity of dysphagia before and one month after the procedure. Results: We report four patients who presented with symptomatic thyroid nodules, complaining of dysphagia at the level of the lower neck. Initial symptom scores were 10, 7, 8, and 2 respectively. Thyroid ultrasound demonstrated esophageal compression in all patients due to the culprit responsible nodules and two thyroid biopsies were done to rule out malignancy. Three patients declined surgery and preferred RFA, while the fourth was a poor surgical candidate. RFA was conducted in each by one endocrinologist. The culprit nodules were targeted for RFA, except in case two which was retrosternal. Therefore, a more superficial same-sided nodule was ablated in case two with the goal of reducing mass effect on that side. All the patients reported improvement in their dysphagia and decline in symptom score a month after the procedure to 0, 4, 2, and 0 respectively. Thyroid US demonstrated improvement of esophageal compression one-month after the procedure. No complications were noted. Conclusion: Thyroid ultrasound is a valuable tool in diagnosing dysphagia due to esophageal compression caused by thyroid nodules and in monitoring the response to therapy. Thyroid RFA is a minimally invasive and effective tool for treating symptomatic thyroid nodules.

Presentation Date: Saturday, June 17, 2023
SAT481 Metastatic Choriocarcinoma, A Rare Cause of hCG-Mediated Hyperthyroidism
Authors: Jain Shailee , Crabtree Matthew , Houston Caroline
Published: October 2023

Disclosure: S. Jain: None. M. Crabtree: None. C. Houston: None.

Background: Structural homology between human chorionic gonadotropin (hCG) and thyrotropin stimulating hormone (TSH) allows high levels of hCG to exert thyrotropic effects via TSH receptors. Although hCG-mediated hyperthyroidism is most frequently encountered in the context of pregnancy, it also occurs rarely as a paraneoplastic syndrome. We present a case of hCG-mediated hyperthyroidism due to metastatic choriocarcinoma in a postmenopausal woman. Case Presentation: A previously healthy 59-year-old woman was evaluated for shortness of breath and found to have multiple lung nodules concerning for metastatic malignancy. Further imaging demonstrated an enlarged heterogeneous uterus with an enlarged endometrial cavity. Endometrial biopsy revealed poorly differentiated carcinoma with some areas of possible squamous differentiation. Subspecialty cytopathology review was requested. One week after biopsy, the patient was brought to the emergency department with acute hypoxic respiratory failure following a seizure. She was found to be febrile, tachycardic, hypertensive, and minimally responsive. Head CT revealed a left frontal brain mass with surrounding vasogenic edema, concerning for metastasis. Laboratory evaluation revealed TSH of 0.03 mIU/L (normal 0.35-4.94) and free T4 of 2.30 ng/dL (normal 0.70-1.48). Thyroid stimulating immunoglobulin was negative. Beta-hCG was found to be significantly elevated at 982,093 mIU/mL after 1:100 dilution. She was started on treatment with propranolol, dexamethasone, and chemotherapy with etoposide and cisplatin. Meanwhile, cytopathology review identified scattered cells with features of choriocarcinoma and positive hCG immunostaining, felt to represent a diagnosis of poorly differentiated choriocarcinoma. After one cycle of chemotherapy, the patient’s beta-hCG decreased to 477,668 mIU/mL and free T4 decreased to 1.05 ng/dL. Due to progressive worsening of her clinical status, she was transitioned to palliative care and passed away on hospital day 14. Discussion: Hyperthyroidism mediated by hCG is most often seen in patients with hyperemesis gravidarum, gestational transient thyrotoxicosis, or gestational trophoblastic disease. Our case underscores the importance of considering hCG-mediated hyperthyroidism outside the context of pregnancy. Rare paraneoplastic sources of hCG include choriocarcinoma, seminoma, and other germ cell tumors. Hyperthyroidism in these cases is usually subclinical or mild, but instances of thyroid storm have been reported with metastatic disease. Beta blockers, glucocorticoids, and thionamides can be used as temporizing measures, but definitive therapy requires treatment of the causative malignancy.

Presentation Date: Saturday, June 17, 2023
SAT528 Evaluation of Fine Needle Aspiration Biopsy Results in Patients with History of Thyroid Surgery for Benign Thyroid Disease
Authors: Can Ahmet Selçuk , Naran Jaya
Published: October 2023

Disclosure: A.S. Can: None. J. Naran: None.

Objective: We aimed to compare our thyroid fine needle aspiration (FNA) biopsy results in patients with history of thyroid surgery for benign thyroid disease and in patients without history of thyroid surgery. Material and Method: FNAs were performed between January 2016 and December 2020. The demographic data and outcomes were reviewed retrospectively. The results were presented per nodule, not per patient. FNA was performed on two groups: Group 1: nodules with history of thyroid surgery for benign thyroid disease, and Group 2: nodules without history of thyroid surgery. FNA results were categorized as malignant, benign, indeterminate, and unsatisfactory. FNAs were performed under ultrasound guidance. Results: 711 thyroid nodules underwent ultrasound guided FNA. 18 FNAs were performed on nodules diagnosed in patients who had history of thyroid surgery for benign thyroid disease (Group 1). Average age and standard deviation (SD) of Group 1 were 63±10 years. Average maximum size of nodules in Group 1 was 20±12 mm and average volume was 5.4±13.0 mL. Group 1 nodules had surgery on average 18±10 years ago. Thirteen nodules had hemithyroidectomy, three subtotal thyroidectomy and two nodule removal only. 693 FNAs were performed on nodules diagnosed in patients without history of thyroid surgery (Group 2). Average age and SD of Group 2 patients were 58±14 years. Average maximum size of nodules in Group 2 was 21±11 mm and average volume was 4.7±9.7 mL. FNA results in Group 1 versus Group 2 nodules were as follows: malignant 0% versus 3% (n=0 versus n=22), benign 72% versus 68% (n=13 versus n=470), indeterminate 6% versus 10% (n=1 versus n=70), unsatisfactory 22% versus 19 % (n=4 versus n=131), Chi-Square= 1.08, degrees of freedom= 3, p= 0.78. There was no statistical difference between groups in biopsy results. The chi-square statistic may not be reliable because two of the expected frequencies were less than 5. Conclusions: We did not observe any malignancy in patients with thyroid nodules who had history of thyroid surgery for benign thyroid disease. FNA performed similarly well whether there was history of thyroid surgery for benign thyroid disease or not. Further studies on larger group of patients with history of thyroid surgery for benign disease can be considered to confirm our findings.

Presentation Date: Saturday, June 17, 2023
SAT530 Use of Tamoxifen and Cabergoline to Suppress Breast Tissue Uptake of Radioactive Iodine Among Differentiated Thyroid Cancer Patients
Authors: Mohamed Abubakr H B , Basina Marina
Published: October 2023

Disclosure: A.H. Mohamed: None. M. Basina: None.

Background: Radioactive iodine (RAI) has been used in thyroid cancer treatment. Physiologic breast tissue uptake and accumulation of RAI are not desirable due to increased carcinogenesis risk. Case1:31 years old non lactating female diagnosed with stage IVB papillary thyroid cancer and underwent total thyroidectomy and bilateral neck dissection. She had high initial risk with stage of T3N1bM1 and underwent 118 mCi of I-131 treatment with pulmonary foci. One year later, she had biochemical and structural incomplete response and underwent I-123 RAI uptake scan demonstrating residual disease in the right neck and diffuse breast uptake, thus, I-131 treatment was deferred. The patient was started on cabergoline 0.5 mg daily for 2 months. Repeated I-123 uptake scan during day 2 of Cabergoline remained with diffuse breast uptake. Four months later, another repeated RAI uptake scan after 4 months showed minimal breast uptake and RAI I-131 treatment was given. She had normal mammogram screening. Case2: 41 years old non lactating female diagnosed with stage II papillary thyroid cancer and underwent total thyroidectomy with right neck dissection. She had moderate initial risk with stage of T3 N1aM0 and underwent 159 mCI of I-131 treatment. Two years later, she had structural incomplete response and repeated I-123 uptake scan showed thyroid bed foci of avid uptake and diffuse bilateral breast uptake, thus, I-131 therapy was deferred. The patient was started on cabergoline 0.25 mg daily for 4 weeks and Tamoxifen 10 mg twice daily for 10 days prior to repeated I-123 RAI scan that redemonstrated thyroid bed foci without breast tissue uptake. She had normal mammogram screening. DiscussionPotential malignancy risk secondary to non-thyroidal RAI accumulation in tissues was reported. The mechanism of breast RAI uptake involves Na/iodide symporter channel regulated by prolactin and estrogen. Blocking the effect of these hormones prior to I-131 administration are believed to prevent breast uptake. We describe two papillary thyroid cancer cases with breast RAI uptake that was suppressed partially with Cabergoline (prolactin lowering agent) and fully with combination of Cabergoline and Tamoxifen (estrogen receptor blocker). Further studies are needed to evaluate the efficacy of Tamoxifen and cabergoline in suppressing physiologic breast RAI uptake.

Presentation Date: Saturday, June 17, 2023
SAT536 A Case of Papillary Thyroid Cancer in Multiple Cervical Lymph Nodes, But Not Found in Thyroid Tissue on Pathology
Authors: Green Maria A , Kim Grace Y
Published: October 2023

Disclosure: M.A. Green: None. G.Y. Kim: None.

Introduction:As technology advances, imaging becomes increasingly frequent and within the thyroid gland nodules can often be detected. After detection comes evaluation and lymph nodes within the neck are an integral part of this step. For that reason, fine needle aspiration (FNA) of cervical lymph nodes is known to lend a hand toward diagnosis. Here we present a patient who was diagnosed with Papillary Thyroid Cancer (PTC) from FNA pathology of a lymph node, but PTC was not noted within pathology of the thyroid tissue after total thyroidectomy. Case Presentation: This patient is a 34 year-old female with a history of ovarian cancer who presented to the clinic for a thyroid nodule and Hashimoto’s disease. A bed side ultrasound noted a right upper pole 1.6 x 0.6 x 0.6 cm thyroid nodule and a solid 1.8 x 1.5 x 0.8 cm nodule superior to the isthmus likely representing a delphian lymph node. As well, significant cervical lymphadenopathy was seen. A biopsy of the right upper pole nodule was nondiagnostic on FNA, but the delphian lymph node superior to the isthmus was positive for PTC. The patient then underwent total thyroidectomy and right and central neck lymph node dissections. Interestingly, PTC was noted in 3 of 27 lymph nodes in the central compartment, 5 of 18 lymph nodes excised with the thyroid tissue with extranodal extension, and 5 of 24 lymph nodes in the right neck compartment, but not noted in the thyroid tissue itself. The largest metastatic dimension of PTC within the cervical lymph nodes was noted to be 3 cm. The pathology noted a 1.0 cm tumor in the right lobe “approaching skeletal muscle” and psammoma bodies within the left lobe. After the patient’s surgery her stimulated thyroglobulin reported as 0.21 NG/mL and thyroglobulin antibody 2 IU/mL. She was then able to receive 30 mCi of I 131 sodium iodide. TSH maintained at goal on levothyroxine 200 mcg daily. Discussion: Diagnosis of PTC within multiple cervical lymph nodes, but not noted on thyroid pathology is very uncommon. It is highly unlikely in our patient that a cancer within the thyroid does not exist and there are theories to postulate this unique finding. These include missed pathology on the dissection, tumor regression prior to removal, or possibly ectopic tissue as the source of PTC. Although in our patient, given the significant amount of positive cervical lymph nodes, it is hard to believe that ectopic tissue away from the neck was the source or that tumor regression occurred. The pathological findings of psammoma bodies suggest the presence of PTC that spread to the lymphatic system. As well, the nature of thyroid removal leads to some destruction of tissue prior to evaluation. This case highlights the importance of thorough lymph node evaluation as a complete part of preoperative PTC assessment.

Presentation Date: Saturday, June 17, 2023
FRI206 A Rare Case Of Coexisting Acromegaly And Adrenal Cushing’s Syndrome
Authors: Chamakkala Tess , Gallagher Thomas
Published: October 2023

Disclosure: T. Chamakkala: None. T. Gallagher: None.

Introduction: Acromegaly has been associated with higher risk of cancer morbidity and mortality. Acromegaly coexisting with adrenal Cushing’s disease has been rarely described in literature. We present a patient who was found to have acromegaly during evaluation for Cushing’s syndrome. Clinical Case: A 50-year-old woman presented to the office for endocrinology evaluation at the referral of PCP for elevated 24h urine cortisol level 176ug/24h. She had noticed facial plethora over several years, fatigue, and easy bruising. She had recently been diagnosed with hypertension, poorly controlled on two medications at the time of evaluation. Repeat 24h urine cortisol and midnight salivary cortisol levels were elevated; dexamethasone suppression test was positive. ACTH was <1.5pg/mL, consistent with ACTH independent hypercortisolemia. Adrenal CT showed 2.6x3cm left adrenal adenoma. She underwent left adrenalectomy and pathology showed adrenal cortical adenoma. During evaluation for Cushing’s disease and new onset hypertension, IGF1 was evaluated and found to be elevated at 354ng/mL. She additionally endorsed symptoms of worsening carpal tunnel syndrome and increasing ring size. After adrenalectomy, IGF1 was repeated and remained elevated at 429ng/mL. Growth hormone suppression test showed nadir of 0.56ng/mL which is higher than <0.3ng/mL expected of high sensitivity GH assays. Pituitary MRI showed three suspected pituitary microadenomas, 4mm and 5mm in left gland, 7mm in right gland. Given difficulty with surgical approach and higher risk of hypopituitarism, she was started on lanreotide for treatment without surgery. She underwent genetic counseling and was offered genetic testing. Conclusion: This case highlights the rare coexistence of acromegaly and adrenal Cushing’s disease in a 50 year old woman. Though the relationship between acromegaly and cancer has been historically controversial, more recent studies have shown an increased risk of both benign and malignant tumors with acromegaly. Untreated Cushing’s Disease has been associated with mildly elevated IGF1 which then decreases after remission; it is unclear if the same pathological process is involved in other etiologies of hypercortisolemia like adrenal Cushing’s syndrome, but re-evaluation of IGF1 after treatment of Cushing’s should be considered. As Cushing’s and acromegaly share similar consequences such as worsening HTN, changing facial appearance, and worsening diabetes, it is prudent to consider each as differential diagnoses when signs do not remit after treatment. Acromegaly has additionally been associated with other endocrinopathies in syndromes including MEN1 syndrome, McCune Albright Syndrome, and Carney Complex. Evaluation for these syndromes and consideration for genetic testing should be considered in the evaluation of a patient with acromegaly and additional associated endocrinopathies.

Presentation: Friday, June 16, 2023
SAT391 Supratherapeutic Estrogen Levels in Transgender Women Likely From Sublingual Estradiol
Authors: Jalal Erica , Baldwin Chelsey
Published: October 2023

Disclosure: E. Jalal: None. C. Baldwin: None.

Transgender medicine is typically managed in the outpatient setting. We report a case where the patient’s hospitalization provided unique insight into hormone management to achieve cis-female range estrogen and testosterone levels in a monitored environment.A 38-year-old transgender woman with HIV (on antiretroviral therapy) complicated by neurocognitive disorder, polysubstance use, mood disorder with previous suicidal ideation, and polytrauma (currently wheelchair bound) was admitted for respiratory failure from MRSA pneumonia. She completed 14 days of antibiotics with resolution of acute medical problems, but ability to secure a safe discharge plan prolonged her hospitalization. Endocrinology was consulted to aid in oral estradiol (E2) management.Prior to admission, patient reported taking 10mg of oral E2 daily. While hospitalized, she was given 6mg E2 daily, but requested resumption of her home dose. Initial total estrogen and testosterone levels were 913 pg/mL (56-213 pg/mL) and 105 ng/dL (264-916 ng/dL), respectively. She denied estrogen pellets, implants, or consumption of additional E2 beyond 6mg daily, nor did she have visitors who provided supplemental hormone; however, she admitted that she does not swallow the E2 pills immediately.Endocrinology initiated intramuscular leuprolide to suppress her total testosterone production to the female range of 0-50 ng/dL, allow for decreased dosing of E2 to maintain female range estrogen levels, and minimize venous thromboembolism (VTE) risk given reduced patient mobility. Her E2 was held for 5 days, with a subsequent total estrogen level of 398 pg/mL (56-213 pg/mL). She was restarted on oral E2 2mg, with total estrogen levels of 238 pg/mL and 517 pg/mL (56-213 pg/mL) at three and six days respectively. Oral E2 was again held for an additional four days, leading to total estrogen level of 119 pg/mL (56-213 pg/mL) and total testosterone of 18 ng/dL (264-916 ng/dL). Her final regimen is now oral E2 1mg daily. She did not develop VTE while hospitalized.Research into the pharmacokinetics of oral versus sublingual E2 is scarce. Differences in absorption explain this patient’s supratherapeutic estrogen level of 913 pg/mL and insufficiently suppressed total testosterone of 105 ng/dL. Sublingual E2 achieves higher peak levels but multi-daily dosing is required to fully suppress testosterone production when compared to its oral counterpart, which corresponds to this patient’s initial laboratory findings. Sublingual E2 also has a lower risk of VTE since it avoids first-pass metabolism. Future research should target alternative routes of estrogen therapy that may potentially be safer than current modalities.

Presentation: Saturday, June 17, 2023
SAT398 Pubertal Status And Trends In Gender Affirming Treatment Of Transgender And Gender Diverse Youth
Authors: Lin Cathy , Oransky Matthew , Fader Ralph , Malhotra Neha R , Baldiserroto Eva M , Romero Christopher Joseph , Safer Joshua D , Yau Mabel
Published: October 2023

Disclosure: C. Lin: None. M. Oransky: None. R. Fader: None. N.R. Malhotra: None. E.M. Baldiserroto: None. C.J. Romero: None. J.D. Safer: None. M. Yau: None.

Background: Transgender and gender diverse (TGD) youth seek care to affirm their gender identities and improve quality of life and mental health. Gender affirming care of youth includes pubertal assessment, pubertal suppression with gonadotropin-releasing hormone agonist (GnRHa) and gender-affirming hormone therapy (GAHT). Management choices are made collaboratively among the patient, the patient’s family, and the multidisciplinary treatment team.

Objective: We sought to characterize the pubertal status of the TGD youth to consider medical intervention.

Method: The medical records of 58 TGD youth referred to pediatric endocrinology from 2020-2022 were retrospectively analyzed. Pubertal assessments were made by visualization of pubic hair and breast development according to the Tanner scale and determination of testicular volume with an orchidometer. We labeled Tanner stage 1 as prepuberty; stages 2-3 as early puberty; and stages 4-5 as late puberty.

Results: The median age was 15 years (range 8-18 years). 46.6% were trans girls (n=27), 44.8% were trans boys (n=26), and 8.6% were non-binary (n=1 natal male and n=4 natal female). Of the trans girls, 7.4% were prepubertal (n=2), 51.9% were in early puberty (n =14), and 40.7% were in late puberty (n=11). Of the trans boys, none were prepubertal, 3.6% were in early puberty (n=1), and 96.4% were in late puberty (n=25). Of the non-binary youth, 20% were in early puberty (n=1) and 80% were in late puberty (n=4).For the prepubertal patients, monitoring for onset of puberty without treatment was recommended. Of the 15 patients in early puberty, 73.3% started GnRHa (10 trans girls, 1 trans boy) and 26.7% started GAHT (4 trans girls). Of the 36 patients in late puberty, 2.8% received no treatment (1 trans boy), 25.0% started GnRHa (7 trans girls, 2 trans boys) and 72.2% started GAHT (4 trans girl, 22 trans boy). Of the 5 non-binary patients, 1 patient in early puberty (1 natal female) was treated with GnRHa, and 4 were in late puberty and initiated on GAHT (1 natal male, 3 natal female).

Conclusion: In our multidisciplinary practice, trans feminine patients are evenly divided between those who present in early and late puberty. This presents possible implications for fertility preservation strategies. Trans masculine patients overwhelmingly present in late puberty, perhaps owing in part to earlier timing for typical “female” puberty. This means that even prompt initiation of GnRHa therapy cannot entirely prevent the potential future need for chest masculinization surgery.

Presentation: Saturday, June 17, 2023
SAT408 Assessment Of Family Planning Readiness In Transgender Youth
Authors: Conard Ryan Steven , Folsom Lisal J
Published: October 2023

Disclosure: R.S. Conard: None. L.J. Folsom: None.

Background: Transgender individuals identify with a gender incongruent with the sex assigned at birth. Some seek medical care in the form of gender affirming hormone therapy (GAHT) or gender affirming surgery (GAS). GAHT initiated in adolescence may include GnRH analogues and cross-sex hormones. Barriers to family planning in this population include low utilization of cryopreservation and decisional regret. There is a paucity of data on the risk of infertility with GAHT, and on to what degree transgender adolescents feel informed about fertility and family planning options.

Objective: To assess knowledge regarding options for family planning and fertility preservation in transgender adolescents treated with GAHT in a pediatric endocrinology gender clinic. The goal is to enhance patient education about potential effects of GAHT on fertility and options for family planning.

Methods: 41 adolescent patients aged 10 years and older treated with GAHT in an urban outpatient pediatric endocrinology clinic were surveyed from January to June 2022. Survey questions were multiple choice, Likert scale, and open-ended. To be included participants were at least 10 years of age, actively followed in the clinic, and receiving GAHT at time of enrollment.

Results: 41 participants completed the survey. Four (10%) expressed interest in discussing family planning with their provider at the time of survey completion. 18 (45%) were open to discussion in the future; 16 (39%) were not interested at all. 13 (32.5%) participants were planning for future parenthood, and 16 (40%) participants were undecided. Of those interested in parenthood 7 (53.8%) planned to adopt or foster. Barriers to family planning expressed included financial concerns, potential need to pause GAHT, and social stigma of transgender parenthood. 20 (50%) participants reported prior family planning discussion with their endocrinologist.

Conclusion: Despite routine family planning discussions documented during visits, these may not be optimally impactful given that 50% of participants did not recall the conversations. Family planning appears to be of lower priority in this population as most desired to postpone discussions with their provider despite undergoing treatment that could influence fertility. Our findings indicate it is essential to actively identify methods to engage transgender youth in discussions related to family planning during GAHT.

Presentation: Saturday, June 17, 2023
SAT646 Cutaneous Manifestations In Adults With Gender Dysphoria Under Treatment Hormonal In External Consultation Of The Hospital De San José , Bogotá Colombia
Authors: Cortes Henry Tovar
Published: October 2023

Disclosure: H. Tovar Cortes: None.

I. Title Cutaneous manifestations in adults with gender dysphoria under treatment hormonal in external consultation of the Hospital de san José , Bogotá .Colombia II. Authors Dr. Manuel Fernando Ortiz Castañeda1, Dr. Henry Tovar Cortes2 , Dra. Nicolle Guiot Isaac3, Dra. Carolina Morales Cardenas3, Dr. Carlos Jimenez4 1. Dermatologist and Instructor or Professor (Assistant, Associate) of the Department of Dermatology Fundación Universitaria de Ciencias de Salud - Hospital de San José de Bogotá 2. Endocrinologist and Instructor or Professor (Assistant, Associate) from the Department of Endocrinology Fundación Universitaria de Ciencias de la Salud - Hospital de San José de Bogotá 3. Third-year residents of Dermatology Fundación Universitaria de Ciencias de la Salud - Hospital de San José de Bogotá 4. Fellow of Endocrinology Foundation University of Health Sciences - Hospital de San José de Bogotá III. Introduction : Comprehensive health care for patients with gender dysphoria includes Access to gender affirmation hormone therapy. It can have skin and annex side effects, which often affect quality of life, are underdiagnosed and not treated promptly. Literature on the subject is scarce. Objective: To determine skin manifestations secondary to hormonal treatment in adults with gender dysphoria. IV. Methodology: Cross-sectional descriptive observational study. A search was carried out in the database of patients with gender dysphoria over 18 years of age, treated in dermatology and/or endocrinology clinic of the San José Hospital of Bogotá in the period 2015-2021. The clinical records of patients who were in hormonal therapy with skin manifestations were selected, patients who used other drugs as possible triggers were excluded. Sociodemographic data, skin manifestations, evaluation by specialists and treatment received were analyzed. V. Results : 85 patients were included, predominantly young transgender men in whom the main manifestation was acne (90%), followed by androgenetic alopecia and acanthosis nigricans. Transgender women presented more acne, androgenetic alopecia, seborrheic dermatitis and melasma. More than half of the patients were seen by endocrinology and dermatology, receiving mainly topical treatment. VI. Discussion and conclusion: Skin manifestations in patients with gender dysphoria in hormonal therapy are frequent, so they should be known and taken into account in the multidisciplinary approach of these patients, including the participation of a dermatologist. VII.

KEYWORDS: Gender dysphoria, Gender identity, Gonadal steroid hormones, Testosterone, Estrogens, Estradiol, Antiandrogens, Androgens VIII. ADDRESS - CONTACT Dr. Henry Tovar Cortés Mail: htovar@fucsalud.edu.co Contact number: 3158849232 Correspondence address: Carrera 18 9-18 , office 103

Presentation: Saturday, June 17, 2023
THU481 Glucocorticoid Regeneration By Tumor Cells Promotes Growth By Enhancing Regulatory T Cell Immunosuppression
Authors: Taves Matthew D , Otsuka Shizuka , Taylor Michaela A , Donahue Kaitlynn M , Ashwell Jonathan D
Published: October 2023

Disclosure: M.D. Taves: None. S. Otsuka: None. M.A. Taylor: None. K.M. Donahue: None. J.D. Ashwell: None.

Glucocorticoids are steroid hormones with potent immunosuppressive properties. Their primary source is the adrenals, where they are generated via de novo synthesis from cholesterol. In addition, many tissues have a recycling pathway in which glucocorticoids are regenerated from inactive metabolites by the enzyme 11β-HSD1 (encoded by Hsd11b1). We found that multiple tumor types express Hsd11b1 and produce active glucocorticoids. Genetic ablation of Hsd11b1 in such cells had no effect on in vitro growth but reduced in vivo tumor progression, which corresponded to increased frequencies of tumor-infiltrating cytotoxic T cells expression activation markers and producing effector cytokines. Tumor-derived glucocorticoids upregulated tumor-infiltrating regulatory T cell (Treg) expression of miRNA-342 and downregulated the mTORC2 component Rictor, enhancing Treg activity. Indeed, cytotoxic T cell activation was restored and tumor growth reduced in mice with Treg-specific glucocorticoid receptor deficiency. Importantly, pharmacological inhibition of 11β-HSD1 reduced tumor growth to the same degree as gene knockout, and rendered immunotherapy-resistant tumors susceptible to immune checkpoint blockade. Given that HSD11B1 is upregulated in many human tumors and that inhibition of 11β-HSD1 is well-tolerated in clinical studies, these data suggest that targeting 11β-HSD1 may be a beneficial adjunct in cancer therapy.

Presentation: Thursday, June 15, 2023
THU484 Distinct Genetic Characteristics In Follicular Thyroid Cancer With Different Metastatic Potentials
Authors: Kwak Soo-jung , Lee Eun Kyung , Song Young Shin , Park Young Joo , Kim Jong-Il
Published: October 2023

Disclosure: S. Kwak: None. E. Lee: None. Y. Park: None.

Although most follicular thyroid cancers (FTCs) show excellent prognosis, more than 5% accompany distant metastasis, often diagnosed unexpectedly in the advanced stage. Genetic or genomic markers have been shown to be useful as a prognostic tool in many cancers, but it is unclear whether genetic markers predicting the metastatic potential of FTCs exist. To investigate, 11 pairs of matched formalin fixed paraffin embedded tissue samples of primary (PTM1) and metastatic tumors (MT) from FTC patients with distant metastasis were analyzed by whole exome sequencing. For validation, 78 unmatched FTC samples including 49 well-differentiated tumors, 15 poorly-differentiated tumors and 14 anaplastic thyroid cancer (ATC) samples were analyzed by targeted sequencing. Among the 11 paired PTM1 and MT tumors, 10 showed concordant driver mutations (NRAS, HRAS, DICER1, EIF1AX), and the TERT promoter mutation was concordantly found in 6 pairs. However, the concordance rate of other somatic mutations in paired samples were found to be only 16.2%. Other mutational characteristics such as mutational signatures and CNVs also differed, suggesting the independent subclonal evolution of the paired MT from the PTM1 after metastasis. Interestingly, the frequency of mutations including driver, TERT promoter, and other mutations was lower in primary tumors without metastases (PTM0). Mutational characteristics of PTM0 also differed from those of PTM1 and MT, suggesting that the mutational or molecular characteristics of PTs at the time of diagnosis may distinguish metastatic potential. In a pooled analysis including published data of follicular patterned tumors, we found that metastatic or aggressive tumors were more likely to have the RAS mutation, which tended to be coupled with TERT, DICER1, EIF1AX, and TP53, gradually from minimally invasive FTC, widely invasive FTC to poorly differentiated thyroid cancer (PDTC) and ATC. Transcriptomic profiles from The Cancer Genome Atlas (TCGA) and our data (SNUH) showed RAS(+)/TERT(+) mutated tumors and RAS(+)/TERT(-) tumors had differences in several intracellular signal pathways. Therefore, when follicular neoplasm is diagnosed, NRAS and HRAS mutation tests followed by TERT promoter mutation tests may help diagnose FTCs with metastatic potential. Other genetic mutations could be candidates for a diagnostic or prognostic marker, and large-scale validation studies are warranted.This study was funded by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT & Future Planning (NRF-2019R1A2C2084332).

Presentation: Thursday, June 15, 2023